Dynatronics Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2681575005
USD
0.05
0 (-0.66%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Dynatronics Corp. stock-summary
stock-summary
Dynatronics Corp.
Pharmaceuticals & Biotechnology
Dynatronics Corporation is a manufacturer and distributor of physical medicine products. The Company's products include a line of medical equipment for physical medicine applications, including therapy devices, medical supplies and soft goods, treatment tables and rehabilitation equipment. Its products are used by physical therapists, chiropractors, sports medicine practitioners, podiatrists, physicians and other physical medicine professionals. Its physical medicine products include therapeutic modalities, such as Dynatron Solaris, including electrotherapy and thermal therapy, and 25 Series, including electrotherapy and ultrasound; manufactured capital products, including traction systems and wood furniture; manufactured supplies, including cold packs, straps, wedges, bolsters and mats; distributed capital products, including hydrotherapy, weight training equipment and pilates, and distributed supplies, including clinical accessories, sports med and taping products, lotions and gels.
Company Coordinates stock-summary
Company Details
7030 S Park Centre Dr Bldg D , SALT LAKE CITY UT : 84121-6618
stock-summary
Tel: 1 801 5687000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (0.23%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Ms. Erin Enright
Independent Chairman of the Board
Mr. John Krier
Chief Executive Officer, Director
Mr. Brian Baker
Director
Mr. David Holtz
Independent Director
Mr. Scott Klosterman
Independent Director
Mr. Brian Larkin
Independent Director
Dr. R. Scott Ward
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
6 Million
(Quarterly Results - Mar 2025)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.25

stock-summary
Return on Equity

-23.53%

stock-summary
Price to Book

0.08